Home > Insider Trading > Filing (0001415889-24-008770)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1798749	Aerovate Therapeutics Inc.	AVTE	Pharmaceutical Preparations (2834)	831377888

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1869248	T Benjamin Dake	C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-18	20,557	$2.14	21,848	No	4	M	Direct
Common Stock	Acquisiton	2024-03-18	14,500	$10.61	36,348	No	4	M	Direct
Common Stock	Disposition	2024-03-18	27,476	$25.74	8,872	No	4	S	Direct
Common Stock	Disposition	2024-03-18	7,581	$26.48	1,291	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-03-18	20,557	$0.00	20,557	$2.14
Common Stock	Stock Option (Right to Buy)	Disposition	2024-03-18	14,500	$0.00	14,500	$10.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
102,789		2031-04-01	No	4	M	Direct
43,500		2031-12-13	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.235 to $26.234, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.
A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.